Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy

被引：16

作者：

Torréns, I

Reyes, O

Ojalvo, AG

Seralena, A

Chinea, G

Cruz, LJ

de la Fuente, J

机构：

[1] Ctr Ingn Genet & Biotecnol, Div Pharmaceut, Havana, Cuba

[2] Ctr Ingn Genet & Biotecnol, Div Phys Chem, Havana, Cuba

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 1999年 / 259卷 / 01期

关键词：

D O I：

10.1006/bbrc.1999.0747

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. Being a bacterial protein, SK is immunogenic in humans. Therefore, resulting from SK therapy, patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. High Ab titers might provoke severe immune reactions during SK therapy and neutralize SK activity, preventing effective thrombolysis. Spot synthesis combined with peptide library techniques is a useful tool for studying protein-peptide interactions on continuous cellulose membranes. Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. All tested samples have high anti-SK Ab titers and most of them show significant SK neutralizing capacity. Individual variations in peptide recognition were detected. However, patients treated with SK tend, in general, to show a common regional binding pattern, including residues 1-20, 130-149, 170-189, and 390-399. This is the first study reporting the probing of a cellulose-bound set of peptides with total human sera. (C) 1999 Academic Press.

引用

页码：162 / 168

页数：7

共 32 条

[11]

GERLACH D, 1977, ZBL BAKT-INT J MED M, V238, P336

[12]

HUNT D, 1992, LANCET, V339, P753

[13]

KRAMER A, 1993, PEPTIDE RES, V6, P314

[14]

KRAMER A, 1994, METHODS COMP METH EN, V6, P912